Evan Dellon, MD, MPH: New Late-Breaking Data on Dupilumab for EoE

New data presented during the 2022 American College of Gastroenterology (ACG) Annual Meeting show dupilumab results in clinical, symptomatic, histologic, endoscopic, and molecular feature improvements for patients with eosinophilic esophagitis (EoE) for up to 52 weeks.

The late-breaking abstract presented by Evan Dellon, MD, MPH, FACG, Professor of Medicine and Adjunct Professor of Epidemiology, Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, show new data from the Parts A and B of the 3-part phase 3 LIBERTY EoE TREET study.

In part A of the study, the investigators compared 300 mg dupilumab weekly dosing with placebo.

Overall, the study drug results in significant efficacy and acceptable safety for up to 24 weeks.

The investigators met the co-primary endpoints in part B of the proportion of patients achieving peak esophageal intraepithelial eosinophil count of 6 or less eos/high power field and absolute change from Part B baseline (BL) in Dysphagia Symptom Score (DSQ) score at week 24.

Dupilumab is a fully human mAb that blocks the shared receptor component for interleukin-4/13, which are key drivers of type 2 inflammation.

In May, the Food and Drug Administration (FDA) approved dupilumab for the treatment of EoE in adult and pediatric patients 12 years and older weighing at least 40 kg.

With this approval, dupilumab is the first treatment in the US indicated for EoE, a disease estimated to affect more than 300,000 patients in the US.

In an interview with HCPLive®, Dellon discussed the new data and why it is important to finally have an approved treatment for EoE.